Published in Proc Natl Acad Sci U S A on February 28, 2008
Cytometry by time-of-flight shows combinatorial cytokine expression and virus-specific cell niches within a continuum of CD8+ T cell phenotypes. Immunity (2012) 5.26
Parallel detection of antigen-specific T-cell responses by multidimensional encoding of MHC multimers. Nat Methods (2009) 2.57
Parasite stage-specific recognition of endogenous Toxoplasma gondii-derived CD8+ T cell epitopes. J Infect Dis (2008) 2.40
The cancer antigenome. EMBO J (2012) 1.78
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc (2012) 1.76
Simultaneous detection of many T-cell specificities using combinatorial tetramer staining. Nat Methods (2009) 1.67
Cowpox virus inhibits the transporter associated with antigen processing to evade T cell recognition. Cell Host Microbe (2009) 1.47
Combinatorial tetramer staining and mass cytometry analysis facilitate T-cell epitope mapping and characterization. Nat Biotechnol (2013) 1.45
The CD8 T-cell response against murine gammaherpesvirus 68 is directed toward a broad repertoire of epitopes from both early and late antigens. J Virol (2008) 1.35
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Viral acute lower respiratory infections impair CD8+ T cells through PD-1. J Clin Invest (2012) 1.31
Differential regulation of effector- and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells. PLoS Pathog (2010) 1.25
Single-cell analysis tools for drug discovery and development. Nat Rev Drug Discov (2015) 1.23
Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med (2012) 1.06
High-throughput identification of potential minor histocompatibility antigens by MHC tetramer-based screening: feasibility and limitations. PLoS One (2011) 1.03
MHC-based detection of antigen-specific CD8+ T cell responses. Cancer Immunol Immunother (2010) 0.98
HLA-F complex without peptide binds to MHC class I protein in the open conformer form. J Immunol (2010) 0.98
T-cell responses to oncogenic merkel cell polyomavirus proteins distinguish patients with merkel cell carcinoma from healthy donors. Clin Cancer Res (2014) 0.94
Conditional ligands for Asian HLA variants facilitate the definition of CD8+ T-cell responses in acute and chronic viral diseases. Eur J Immunol (2013) 0.92
Concurrent detection of circulating minor histocompatibility antigen-specific CD8+ T cells in SCT recipients by combinatorial encoding MHC multimers. PLoS One (2011) 0.90
5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies. Blood Cancer J (2014) 0.89
Application of the pMHC Array to Characterise Tumour Antigen Specific T Cell Populations in Leukaemia Patients at Disease Diagnosis. PLoS One (2015) 0.89
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control? Front Immunol (2014) 0.86
Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol (2016) 0.81
Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics (2011) 0.81
Broadening the repertoire of melanoma-associated T-cell epitopes. Cancer Immunol Immunother (2015) 0.79
Stability screening of arrays of major histocompatibility complexes on combinatorially encoded flow cytometry beads. J Biol Chem (2011) 0.79
Definition of Proteasomal Peptide Splicing Rules for High-Efficiency Spliced Peptide Presentation by MHC Class I Molecules. J Immunol (2015) 0.78
Peptide Splicing in the Proteasome Creates a Novel Type of Antigen with an Isopeptide Linkage. J Immunol (2015) 0.77
Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunol Res (2016) 0.76
Evolution of MHC-based technologies used for detection of antigen-responsive T cells. Cancer Immunol Immunother (2017) 0.75
Testing for HLA/peptide tetramer-binding to the T cell receptor complex on human T lymphocytes. Results Immunol (2012) 0.75
Detecting Antigen-Specific T Cell Responses: From Bulk Populations to Single Cells. Int J Mol Sci (2015) 0.75
Binding of TCR multimers and a TCR-like antibody with distinct fine-specificities is dependent on the surface density of HLA complexes. PLoS One (2012) 0.75
Influence of ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget (2017) 0.75
Photochemical approaches to T-cell activation. Immunology (2010) 0.75
Identification of an immunogenic neo-epitope encoded by mouse sarcoma using CXCR3 ligand mRNAs as sensors. Oncoimmunology (2017) 0.75
Identification of the core regulators of the HLA I-peptide binding process. Sci Rep (2017) 0.75
Novel HLA-A2-restricted human metapneumovirus epitopes reduce viral titers in mice and are recognized by human T cells. Vaccine (2016) 0.75
Chemical Modification of Influenza CD8+ T-Cell Epitopes Enhances Their Immunogenicity Regardless of Immunodominance. PLoS One (2016) 0.75
Phenotypic analysis of antigen-specific T lymphocytes. Science (1996) 24.26
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics (1999) 14.15
The immune epitope database and analysis resource: from vision to blueprint. PLoS Biol (2005) 7.40
Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med (2005) 7.18
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
HLA-A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides. Proc Natl Acad Sci U S A (1992) 5.02
Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med (2006) 4.54
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44
T-cell-receptor gene therapy. Nat Rev Immunol (2002) 3.31
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat Immunol (2001) 2.79
Molecules and mechanisms of the graft-versus-leukaemia effect. Nat Rev Cancer (2004) 2.65
Adoptive transfer of cytomegalovirus-specific CTL to stem cell transplant patients after selection by HLA-peptide tetramers. J Exp Med (2005) 2.54
A new look at T cells. J Exp Med (1998) 2.51
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Immunotherapy through TCR gene transfer. Nat Immunol (2001) 2.41
Structural characterization of a soluble and partially folded class I major histocompatibility heavy chain/beta 2m heterodimer. Nat Struct Biol (1998) 1.82
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction. Tissue Antigens (2002) 1.68
Detection and characterization of cellular immune responses using peptide-MHC microarrays. PLoS Biol (2003) 1.62
Selective expansion of cross-reactive CD8(+) memory T cells by viral variants. J Exp Med (1999) 1.58
Analysis of interactions in a tapasin/class I complex provides a mechanism for peptide selection. EMBO J (2007) 1.56
Reversible MHC multimer staining for functional isolation of T-cell populations and effective adoptive transfer. Nat Med (2002) 1.54
Marked differences in human melanoma antigen-specific T cell responsiveness after vaccination using a functional microarray. PLoS Med (2005) 1.42
Cellular immunotherapy for viral infection after HSC transplantation. Nat Rev Immunol (2005) 1.33
Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. J Immunol (1998) 1.24
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
HLA-restricted epitope identification and detection of functional T cell responses by using MHC-peptide and costimulatory microarrays. Proc Natl Acad Sci U S A (2005) 1.21
CD8 T cells, like CD4 T cells, are triggered by multivalent engagement of TCRs by MHC-peptide ligands but not by monovalent engagement. J Immunol (2006) 1.06
Shared epitopes for HLA-A3-restricted melanoma-reactive human CTL include a naturally processed epitope from Pmel-17/gp100. J Immunol (1996) 1.05
Structures of HLA-A*1101 complexed with immunodominant nonamer and decamer HIV-1 epitopes clearly reveal the presence of a middle, secondary anchor residue. J Immunol (2004) 1.03
Real-time measurement of in vitro peptide binding to soluble HLA-A*0201 by fluorescence polarization. Biochemistry (2004) 1.03
Identification of gp100-derived, melanoma-specific cytotoxic T-lymphocyte epitopes restricted by HLA-A3 supertype molecules by primary in vitro immunization with peptide-pulsed dendritic cells. Int J Cancer (1998) 1.02
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2005) 0.97
A sensitive fluorometric assay for quantitatively measuring specific peptide binding to HLA class I and class II molecules. J Immunol Methods (1997) 0.83
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. J Clin Oncol (2013) 5.23
Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature (2012) 3.77
Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood (2008) 3.65
Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem Biol (2002) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Design and use of conditional MHC class I ligands. Nat Med (2006) 3.01
Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy. Nat Med (2010) 2.92
Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol Cell (2005) 2.76
Structure of the ubiquitin hydrolase UCH-L3 complexed with a suicide substrate. J Biol Chem (2004) 2.75
Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome. Structure (2006) 2.56
Heterogeneous differentiation patterns of individual CD8+ T cells. Science (2013) 2.54
Generation of peptide-MHC class I complexes through UV-mediated ligand exchange. Nat Protoc (2006) 2.47
Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc Natl Acad Sci U S A (2003) 2.32
Allo-HLA reactivity of virus-specific memory T cells is common. Blood (2010) 2.28
Zinc-finger protein A20, a regulator of inflammation and cell survival, has de-ubiquitinating activity. Biochem J (2004) 2.23
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci U S A (2013) 2.12
Differential dependence of CD4+CD25+ regulatory and natural killer-like T cells on signals leading to NF-kappaB activation. Proc Natl Acad Sci U S A (2004) 2.09
Stabilization of the transcription factor Foxp3 by the deubiquitinase USP7 increases Treg-cell-suppressive capacity. Immunity (2013) 2.05
OTU deubiquitinases reveal mechanisms of linkage specificity and enable ubiquitin chain restriction analysis. Cell (2013) 2.05
Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice. Exp Hematol (2002) 2.05
Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators. Blood (2010) 2.01
Disease-associated prion protein oligomers inhibit the 26S proteasome. Mol Cell (2007) 2.01
Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol (2004) 1.86
Chemical synthesis of ubiquitin, ubiquitin-based probes, and diubiquitin. Angew Chem Int Ed Engl (2010) 1.83
Antigen bias in T cell cross-priming. Science (2004) 1.82
Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol (2011) 1.81
Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A (2010) 1.80
Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods (2005) 1.78
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patients. Oncoimmunology (2012) 1.78
The cancer antigenome. EMBO J (2012) 1.78
Parallel detection of antigen-specific T cell responses by combinatorial encoding of MHC multimers. Nat Protoc (2012) 1.76
Recruitment of antigen-specific CD8+ T cells in response to infection is markedly efficient. Science (2009) 1.70
Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific. Blood (2011) 1.66
A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med (2005) 1.61
The differential modulation of USP activity by internal regulatory domains, interactors and eight ubiquitin chain types. Chem Biol (2011) 1.58
Mechanism of USP7/HAUSP activation by its C-terminal ubiquitin-like domain and allosteric regulation by GMP-synthetase. Mol Cell (2011) 1.56
Adult and cord blood T cells can acquire HA-1 specificity through HA-1 T-cell receptor gene transfer. Haematologica (2005) 1.56
Mixed T cell receptor dimers harbor potentially harmful neoreactivity. Proc Natl Acad Sci U S A (2010) 1.56
One naive T cell, multiple fates in CD8+ T cell differentiation. J Exp Med (2010) 1.55
An ankyrin-repeat ubiquitin-binding domain determines TRABID's specificity for atypical ubiquitin chains. Nat Struct Mol Biol (2011) 1.55
CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. Blood (2007) 1.54
In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nat Med (2002) 1.54
A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. Chem Biol (2006) 1.54
Dissecting T cell lineage relationships by cellular barcoding. J Exp Med (2008) 1.53
Dissection of T-cell antigen specificity in human melanoma. Cancer Res (2012) 1.52
Adoptive transfer of T-cell immunity. Trends Immunol (2002) 1.50
Tumor rejection induced by CD70-mediated quantitative and qualitative effects on effector CD8+ T cell formation. J Exp Med (2004) 1.46
Differential kinetics of antigen-specific CD4+ and CD8+ T cell responses in the regression of retrovirus-induced sarcomas. J Immunol (2002) 1.46
The deubiquitinating enzyme UCH-L3 regulates the apical membrane recycling of the epithelial sodium channel. J Biol Chem (2007) 1.43
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma. Cancer Immunol Immunother (2014) 1.42
High-throughput identification of antigen-specific TCRs by TCR gene capture. Nat Med (2013) 1.40
Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood (2006) 1.40
Single-cell perforin and granzyme expression reveals the anatomical localization of effector CD8+ T cells in influenza virus-infected mice. Proc Natl Acad Sci U S A (2003) 1.39
Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells. J Am Chem Soc (2009) 1.34
Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol (2010) 1.33
On terminal alkynes that can react with active-site cysteine nucleophiles in proteases. J Am Chem Soc (2013) 1.32
Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin. Nat Commun (2013) 1.31
Elevated p53 expression is associated with dysregulation of the ubiquitin-proteasome system in dilated cardiomyopathy. Cardiovasc Res (2008) 1.28
Two novel ubiquitin-fold modifier 1 (Ufm1)-specific proteases, UfSP1 and UfSP2. J Biol Chem (2006) 1.26
Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res (2006) 1.25
Selecting highly affine and well-expressed TCRs for gene therapy of melanoma. Blood (2007) 1.25
T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother (2008) 1.24
MHC multimer technology: current status and future prospects. Curr Opin Immunol (2005) 1.24
Recombination-induced tag exchange to track old and new proteins. Proc Natl Acad Sci U S A (2009) 1.23
Autotaxin and its product lysophosphatidic acid suppress brown adipose differentiation and promote diet-induced obesity in mice. Mol Endocrinol (2012) 1.21
Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition. Proc Natl Acad Sci U S A (2003) 1.20
Intravital imaging of fluorescent markers and FRET probes by DNA tattooing. BMC Biotechnol (2007) 1.19
Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines. Mol Carcinog (2006) 1.17
Constitutive lymphocyte transmigration across the basal lamina of high endothelial venules is regulated by the autotaxin/lysophosphatidic acid axis. J Immunol (2013) 1.16
Immunotherapeutic potential for ceramide-based activators of iNKT cells. Trends Pharmacol Sci (2005) 1.16
Generation of T cell help through a MHC class I-restricted TCR. J Immunol (2006) 1.15
Ubiquitin-specific protease-like 1 (USPL1) is a SUMO isopeptidase with essential, non-catalytic functions. EMBO Rep (2012) 1.15
Designer T cells by T cell receptor replacement. Eur J Immunol (2006) 1.14
Preclinical development of T cell receptor gene therapy. Curr Opin Immunol (2009) 1.14
A Genome-wide multidimensional RNAi screen reveals pathways controlling MHC class II antigen presentation. Cell (2011) 1.14
An early HIV mutation within an HLA-B*57-restricted T cell epitope abrogates binding to the killer inhibitory receptor 3DL1. J Virol (2011) 1.13
The human leukocyte antigen-presented ligandome of B lymphocytes. Mol Cell Proteomics (2013) 1.13
Automated online sequential isotope labeling for protein quantitation applied to proteasome tissue-specific diversity. Mol Cell Proteomics (2008) 1.13
Chemical evolution of autotaxin inhibitors. Chem Rev (2012) 1.12
Pairing of T-cell receptor chains via emulsion PCR. Eur J Immunol (2013) 1.12
Prospects and limitations of T cell receptor gene therapy. Curr Gene Ther (2011) 1.11
Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res (2008) 1.11